Drug resistance mechanism of PncA in Mycobacterium tuberculosis

Journal of Biomolecular Structure and Dynamics

Volumn 32, Issue 2, 2014, Pages 209-221

  Rajendran, Vidya ^a   Sethumadhavan, Rao ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Docking; Molecular dynamic simulation; Pyrazinamidase; Pyrazinamide; Resistance

Indexed keywords

BACTERIAL ENZYME; MUTANT PROTEIN; PYRAZINAMIDASE; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME METABOLISM; GENE MUTATION; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; BINDING SITES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HYDROGEN BONDING; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MYCOBACTERIUM TUBERCULOSIS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PYRAZINAMIDE; TUBERCULOSIS;

EID: 84889685004     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2012.759885     Document Type: Article

References (60)

1. Agarwal, P. K., Edelsbrunner, H., Harer, J., & Wang, Y. (2006). Extreme elevation on a 2-manifold. Discrete Comput Geom, 36, 553-572.
2. Amadei, A., Linssen, A. B., & Berendsen, H. J. (1993). Essential dynamics of proteins. Proteins, 17, 412-425.
3. Baran, M., & Mazerski, J. (2002). Molecular modelling of membrane sterols with the use of the GROMOS 96 force field. Chemistry and Physics of Lipids, 120, 21-31.
4. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., Dinola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. Journal of Chemical Physics, 81, 3684-3690.
5. Berman, H. M., Battistuz, T., Bhat, T. N., Bluhm, W. F., Bourne, P. E., Burkhardt, K., ... Zardecki, C. (2002). The protein data bank. Acta Crystallographica. Section D, Biological Crystallography, 58, 899-907.
6. Chang, K. C., Yew, W. W., & Zhang, Y. (2011). Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: A systematic review with meta-analyses. Antimicrobial Agents and Chemotherapy, 55, 4499-4505.
7. Chothia, C., & Janin, J. (1975). Principles of protein-protein recognition. Nature, 256, 705-708.
8. Cole, J. C., Murray, C. W., Nissink, J. W., Taylor, R. D., & Taylor, R. (2005). Comparing protein-ligand docking programs is difficult. Proteins, 60, 325-332.
9. Coleman, R. G., Burr, M. A., Souvaine, D. L., & Cheng, C. (2005). An intuitive approach to measuring protein surface curvature. Proteins, 61, 1068-1074.
10. Coleman, R. G., & Sharp, K. M. (2006). Travel depth, a new shape descriptor for macromolecules: Application to ligand binding. Journal of Molecular Biology, 362, 441-458.
11. da Cunha, E. F., Ramalho, T. C., Mancini, D. T., Fonseca, M. B., & Oliveira, A. A. (2010). New approaches to the development of anti-protozoan drug candidates: A review of patents. Journal of the Brazilian Chemical Society, 21, 1787-1806.
12. Dooley, K. E., Mitnick, C. D., Ann DeGroote, M., Obuku, E., Belitsky, V., Hamilton, C. D., ..., Nuermberger, E., & Efficacy Subgroup, RESIST-TB (2012). Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clinical Infectious Diseases, 55, 572-578.
13. Du, X., Wang, W., Kim, R., Yakota, H., Nguyen, H., & Kim, S. H. (2001). Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry, 40, 14166-14172.
14. Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., & Liang, J. (2006). CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acid Research, 34, 116-118.
15. Eckenhoff, R. G., & Johansson, J. S. (1997). Molecular interactions between inhaled anesthetics and proteins. Pharmacological Reviews, 49, 343-367.
16. Eisenhabe, F., & Argos, P. (1996). Hydrophobic regions on protein surfaces: definition based on hydration shell structure and a quick method for their computation. Protein Engineering, 9, 1121-1133.
17. Emekli, U., Schneidman-Duhovny, D., Wolfson, H. J., Nussinov, R., & Haliloglu, T. (2008). HingeProt: Automated prediction of hinges in protein structures. Proteins, 70, 1219-1227.
18. Emsley, P., & Cowtan, K. (2004). Coot: Model-building tools for molecular graphics. Acta Crystallographica. Section D, Biological Crystallography, 60, 2126-2132.
19. Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. Journal of Chemical Physics, 103, 8577-8593.
20. Feldman, H. J., Snyder, K. A., Ticoll, A., Pintilie, G., & Hogue, C. W. (2006). A complete small molecule dataset from the protein data bank. FEBS Letters, 580, 1649-1653.
21. Gonzalez-Martin, J., Garcia-Garcia, J. M., Anibarro, L., Vidal, R., Esteban, J., Blanquer, R., ... Ruiz-Manzano, J. (2010). Consensus document on the diagnosis, treatment and prevention of tuberculosis. Archivos de Bronconeumologia, 46, 255-274.
22. Heifets, L. B., & Cangelosi, G. A. (1999). Drug susceptibility testing of Mycobacterium tuberculosis: A neglected problem at the turn of the century. International Journal of Tuberculosis and Lung Disease, 3, 564-581.
23. Heifets, L. B., & Lindholm-Levy, P. (1992). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis, 145, 1223-1225.
24. Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4, 435-447.
25. Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14, 33-38.
26. Konno, K., Feldmann, F. M., & McDermott, W. (1967). Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis, 95, 461-469.
27. Kumar, A., & Purohit, R. (2012a). Computational investigation of pathogenic nsSNPs in CEP63 protein. Gene, 503, 75-82.
28. Kumar, A., & Purohit, R. (2012b). Computational centrosomics: An approach to understand the dynamic behaviour of centrosome. Gene, 511, 125-126.
29. Kumar, A., & Purohit, R. (2012c). Computational screening and molecular dynamics simulation of disease associated nsSNPs in CENP-E. Mutation Research, 738-739, 28-37.
30. Kumar, A., Rajendran, V., Sethumadhavan, R. & Purohit, R. (2012). In silico prediction of a diseaseassociated STIL mutant and its affect on the recruitment of centromere protein J (CENPJ). FEBS Open Bio, 2, 285-293.
31. Lemaitre, N., Callebaut, I., Frenois, F., Jarlier, V., & Sougakoff, W. (2001). Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. Biochemical Journal, 353, 453-458.
32. Lemaitre, N., Sougakoff, W., Truffot-Pernot, C., & Jarlier, V. (1999). Characterization of new mutations in pyrazinamideresistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemotherapy, 43, 1761-1763.
33. Leung, C. C., Rieder, H. L., Lange, C., & Yew, W. W. (2011). Treatment of latent infection with Mycobacterium tuberculosis: Update 2010. European Respiratory Journal, 37, 690-711.
34. Liang, J., Edelsbrunner, H., & Woodward, C. (1998). Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Science, 7, 1884-1897.
35. McQuade Billingsley, K., Smith, N., Shirley, R., Achieng, L., & Keiser, P. (2011). A quality assessment tool for tuberculosis control activities in resource limited settings. Tuberculosis, 91, 49-53.
36. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. Journal of Computational Chemistry, 19, 1639-1662.
37. Nayal, M., & Honig, B. (2006). On the nature of cavities on protein surfaces: Application to the identification of drugbinding sites. Proteins, 63, 892-906.
38. Pandey, S., Newton, S., Upton, A., Roberts, S., & Drinković, D. (2009). Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology, 41, 582-586.
39. Petrella, S., Gelus-Ziental, N., Maudry, A., Laurans, C., Boudjelloul, R., & Sougakoff, W. (2011). Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: Insights into natural and acquired resistance to pyrazinamide. PLoS ONE, 24, 15785.
40. Purohit, R., Rajasekaran, R., Sudandiradoss, C., George Priya Doss, C., Ramanathan, K., & Sethumadhavan, R. (2008). Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants. International Journal of Biological Macromolecules, 42, 386-391.
41. Purohit, R., Rajendran, V., & Sethumadhavan, R. (2011a). Relationship between mutation of serine residue at 315th position in M. tuberculosis catalase-peroxidase enzyme and Isoniazid susceptibility: An in silico analysis. Journal of Molecular Modeling, 17, 869-877.
42. Purohit, R., Rajendran, V., & Sethumadhavan, R. (2011b). Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants. Journal of Biomolecular Structure & Dynamics, 29, 137-152.
43. Purohit, R., & Sethumadhavan, R. (2009). Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease. Interdisciplinary science, 1, 320-328.
44. Rajendran V., Purohit R., & Sethumadhavan, R. (2012). In silico investigation of molecular mechanism of laminopathy cause by a point mutation (R482W) in lamin A/C protein. Amino Acids, 43, 603-615.
45. Rodriguez, R., Chinea, G., Lopez, N., Pons, T., & Vriend, G. (1998). Homology modeling, model and software evaluation: Three related resources. Bioinformatics, 14, 523-528.
46. Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2005). PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Research, 33, 363-367.
47. Schneidman-Duhovny, D., Nussinov, R., & Wolfson, H. J. (2007). Automatic prediction of protein interactions with large scale motion. Protein, 69, 764-773.
48. Scorpio, A., & Zhang, Y. (1996). Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamie in tubercle bacillus. Nature Medicine, 2, 662-667.
49. Sheen, P., Ferrer, P., Gilman, R. H., Lopez-Llano, J., Fuentes, P., Valencia, E., & Zimic, M. J. (2009). Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis, 89, 109-113.
50. Vallone, B., Miele, A. E., Vecchini, P., Chiancone, E., & Brunori, M. (1998). Free energy of burying hydrophobic residues in the interface between protein subunits. Proceedings of the National Academy of Sciences USA, 95, 6103-6107.
51. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26, 1701-1718.
52. Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., ... Global Project on Anti-Tuberculosis Drug Resistance Surveillance (2009). Epidemiology of antituberculosis drug resistance 2002-07: An update analysis of the Global Project on Anti-tuberculosis Drug Resistance Surveillance. Lancet, 373, 1861-1873.
53. Young, L., Jernigan, R. L., & Covell, D. G. (1994). A role for surface hydrophobicity in protein-protein recognition. Protein Science, 3, 717-729.
54. Yu, J., Wei, W., Danner, E., Ashley, R. K., Israelachvili, J. N., & Waite, J. H. (2011). Mussel protein adhesion depends on interprotein thiol-mediated redox modulation. Nature Chemical Biology, 7, 588-590.
55. Yüksel, P., & Tansel, O. (2009). Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey. New Microbiologica, 32, 153-158.
56. Zhang, H., Deng, J. Y., Bi, L. J., Zhou, Y. F., Zhang, Z. P., Zhang, C. G., ... Zhang, X. E. (2008). Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase. FEBS Journal, 275, 753-762.
57. Zhang, Y., & Mitchison, D. (2003). The curious characteristics of pyrazinamide: A review. International Journal of Tuberculosis and Lung Disease, 7, 6-21.
58. Zhang, C., Vasmatzis, G., Cornette, J. L., & DeLisi, C. (1997). Determination of atomic desolvation energies from the structures of crystallized proteins. Journal of Molecular Biology, 267, 707-726.
59. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H., & Sun, Z. (2003). Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetic by pyrazinoic acid. Journal of Antimicrobial Chemotherapy, 52, 790-795.
60. Zhang, J. L., Zheng, Q. C., Li, Z. Q., & Zhang, H. X. (2012). Molecular dynamics simulations suggest ligand's binding to nicotinamidase/ pyrazinamidase. PLoS ONE, 7, 39546.